This is consistent with previous studies which have demonstrated a downregulation in TSPO expression from baseline in several neurological and psychiatric disorders, including PTSD (Gavish et al., 1996), depression (Chelli et al., 2008; Sarubin et al., 2016), and reduced TSPO ligand binding in PET imaging of recent onset schizophrenia (Notter et al., 2018a), despite the induction of systemic cytokine immune responses. The gene discussed is TSPO; the disease is depressive disorder.